Location [1]
Receptor tyrosine kinase/growth factor signaling
Protein [2]
Vascular endothelial growth factor receptor 3
Synonyms [1]

Fms-related tyrosine kinase 4 (FLT4) is a gene that encodes a protein that is a receptor tyrosine kinase in the vascular endothelial growth factor receptor (VEGF) family. Missense mutations, nonsense mutations, silent mutations, and frameshift deletions are observed in cancers such as intestinal cancer, skin cancer, and stomach cancer.

FLT4 is altered in 3.22% of all cancers with non-small cell lung carcinoma, colorectal adenocarcinoma, melanoma, breast carcinoma, and malignant glioma having the greatest prevalence of alterations [3].

FLT4 GENIE Cases - Top Diseases

The most common alterations in FLT4 are FLT4 Mutation (3.01%), FLT4 Missense (2.75%), FLT4 Frameshift (0.17%), FLT4 Nonsense (0.11%), and FLT4 Loss (0.09%) [3].

FLT4 GENIE Cases - Top Alterations

Significance of FLT4 in Diseases

Malignant Solid Tumor +

Non-Small Cell Lung Carcinoma +

Multiple Myeloma +

Nasal Cavity And Paranasal Sinus Carcinoma +

Adenocarcinoma Of The Gastroesophageal Junction +

Esophageal Carcinoma +

Gastric Carcinoma +

Nasopharyngeal Carcinoma +

Urothelial Carcinoma +

Pancreatic Carcinoma +

Lymphoma +

B-Cell Non-Hodgkin Lymphoma +

Gastrointestinal Stromal Tumor +

Non-Hodgkin Lymphoma +

Cancer +

Hepatobiliary Neoplasm +

Lip And Oral Cavity Carcinoma +

Malignant Laryngeal Neoplasm +

Malignant Salivary Gland Neoplasm +

Oropharyngeal Carcinoma +


1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20170629. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.